SCHEMBL3765753

SCHEMBL3765753

Cc1cccc(C)c1N1CCN(CC(=O)N2CCN(C3CCCCC3)CC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.52
MAPT P10636 4/20 0.51
POLB P06746 1/20 0.51
KDM4E B2RXH2 3/20 0.49
NPSR1 Q6W5P4 2/20 0.47
HTT P42858 1/20 0.47
RGS12 O14924 1/20 0.47
MEN1 O00255 2/20 0.46
TSHR P16473 2/20 0.46
KMT2A Q03164 2/20 0.46
PARP1 P09874 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771221 0.99 ALDH1A1 (0.52) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3772561 0.96 ALDH1A1 (0.52) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL20122620 0.87 TSHR (0.58) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3775910 0.87 MAPT (0.60) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3763088 0.87 TSHR (0.58) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3774214 0.86 TSHR (0.56) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3774250 0.85 MAPT (0.60) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3767997 0.84 TSHR (0.53) ALDH1A1MAPTPOLBKDM4EMEN1
SCHEMBL3763154 0.83 MEN1 (0.55) ALDH1A1MAPTPOLBKDM4ENPSR1
SCHEMBL3763003 0.82 CCR5 (0.58) ALDH1A1POLBKDM4ENPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885MAPT 1475/4885POLB 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.